Skip to main
STRO
STRO logo

STRO Stock Forecast & Price Target

STRO Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 23%
Hold 23%
Sell 8%
Strong Sell 0%

Bulls say

Sutro Biopharma Inc. is demonstrating promising advancements in its clinical development pipeline, particularly with STRO-004 showing enhanced safety and efficacy through its innovative design, leading to improved anti-tumor activity in multiple cancer models. The company is strategically restructuring to optimize capital allocation, which includes a notable workforce reduction projected to decrease operating expenses by 50-70% starting in 2Q25, thereby enhancing financial sustainability through 2026. Additionally, the introduction of STRO-006, with its selective antibody design aimed at integrating β6 ADC, positions Sutro with competitive advantages in a rapidly evolving biopharmaceutical landscape.

Bears say

Sutro Biopharma's financial outlook has deteriorated significantly due to several critical factors, including a projected net loss of $227.4 million for FY24, alongside a decrease in cash reserves from $388.3 million to $316.9 million, which could limit further development activities. The company faces substantial risks regarding clinical results for its lead antibody-drug conjugate (ADC) candidates, which, if underperforming, could lead to downward adjustments in market penetration and timelines for approval, further impacting the share price negatively. Additionally, the recent decision to reduce workforce by nearly 50% and discontinue the luvelta program, once central to its valuation, signal a strategic pivot that could hinder growth prospects and investor confidence.

STRO has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 23% recommend Buy, 23% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sutro Biopharma Inc (STRO) Forecast

Analysts have given STRO a Buy based on their latest research and market trends.

According to 13 analysts, STRO has a Buy consensus rating as of Aug 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sutro Biopharma Inc (STRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.